Latest news

• CHMP backs Sanofi’s all-oral sleeping sickness drug

  Among these, Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) was recommended for the treatment of women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant

• Novartis claims a rare win at ESMO for PI3K inhibitor class

  6 inhibitor, a newer drug group which includes Novartis’ own Kisqali (ribociclib), Pfizer’s Ibrance (palbociclib) and Eli Lilly’s Verzenio (abemaciclib).

• Lilly gets EMA nod for Verzenio in breast cancer

  Sales in the second quarter reached almost $58m, a $20m increase on the first quarter, and Lilly claims it is outperforming Kisqali when it comes to new prescriptions. ... Kisqali’s second-quarter haul was $59m, up from $44m in the first quarter, with

• Novartis considers filings for PI3K drug in breast cancer

  own Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib).

• Daily Brief: Dementia Fund hits $350m mark, hard Brexit could cost £100bn in trade and troublesome results for Pfizer’s Ibrance

  status. However, just weeks after Novartis released promising progressive-free survival data for its Kisqali combo, Pfizer saw its drug flop on the harder overall survival (OS) endpoint.